11.05MMarket Cap-0.13P/E (TTM)
1.854High1.670Low100.06KVolume1.820Open1.850Pre Close178.07KTurnover2.14%Turnover RatioLossP/E (Static)6.32MShares22.04852wk High145.83P/B8.17MFloat Cap1.67052wk Low--Dividend TTM4.67MShs Float1252.000Historical High--Div YieldTTM9.96%Amplitude1.670Historical Low1.779Avg Price1Lot Size
Evaxion Biotech Stock Forum
Groundbreaking AI Cancer Vaccine Shows Promise: Phase 2 Data Reveals Critical Insights
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; F...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, I...
Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package
Tuesday, 25th February at 8:00 am
Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data
The additional third year of EVX-01 dosing may provide further insights into potential enhanced treatment effects and durability of induced immune response
The trial already yielded convin...
Evaxion Extends Phase 2 Trial With Personalized Cancer Vaccine Evx-01 to Further Enhance Clinical Data Package
Financial Turnaround: Evaxion Secures Future with $17M Raise, Dodges Delisting
Nasdaq Confirms Evaxion Is Fully Compliant, Withdraws Delisting Determination
No comment yet